Related scientific articles (all)

Anemia in the elderly.

Authors : Maerevoet M, Sattar L, Bron D, Gulbis B, Pepersack T
Year : 2014
Journal : Rev Med Brux
Volume : 35(4)
Pages : 361-7

Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved?

Authors : Latifyan SB, Vanhaeverbeek M, Klastersky J
Year : 2014
Journal : BMJ Case Rep
Volume : 2014(null)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01).

Authors : de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber Rd, Piccart-Gebhart M, Suter TM
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(20)
Pages : 2159-65

Biology of breast cancer in young women.

Authors : Azim HA, Partridge AH
Year : 2014
Journal : Breast Cancer Res
Volume : 16(4)
Pages : 427

Febrile Neutropenia in pocket Books for Cancer Supportive Care (2014), Springer Healthcare

Authors : Klastersky J
Year : 2014
Journal : Book
Volume : -
Pages : -

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Authors : Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart-Gebhart M, Detours V, Sotiriou C, Haibe-Kains B
Year : 2014
Journal : BMC Genomics
Volume : 15(1)
Pages : 1008

Cardiotoxicity of systemic agents used in breast cancer.

Authors : Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E
Year : 2014
Journal : Breast
Volume : 23(4)
Pages : 317-328

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Authors : Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart-Gebhart M, Flamen P, Hendlisz A
Year : 2014
Journal : BMC Cancer
Volume : 14(1)
Pages : 385

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.

Authors : Raymond E, Alexandre J, Faivre S, Goldwasser F, Besse-Hammer T, Gianella-Borradori A, Jego V, Trandafir L, Rejeb N, Awada A
Year : 2014
Journal : Invest New Drugs
Volume : 32(1)
Pages : 94-103

Adverse events of targeted therapies.

Authors : Klastersky J
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(4)
Pages : 395-402

Deciphering clonality in aneuploid tumors using SNP array and sequencing data.

Authors : Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP
Year : 2014
Journal : Genome Biol.
Volume : 15(9)
Pages : 470

Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Authors : Polastro L, Aftimos P, Awada A
Year : 2014
Journal : Expert Rev Anticancer Ther
Volume : 14(6)
Pages : 649-65

Hurdles and delays in access to anti-cancer drugs in Europe.

Authors : Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart-Gebhart M, Parent F
Year : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 482

Adjuvant and neoadjuvant chemotherapy regimens in breast cancer: summary from the BSMO breast cancer task force meeting.

Authors : Wildiers H, Denys H, Fontaine C, Awada A
Year : 2014
Journal : Belgian J Medical Oncology
Volume : 8(4)
Pages : 116-124

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Authors : Sonnenblick A, Fumagalli D, Sotiriou C, Piccart-Gebhart M
Year : 2014
Journal : Cancer Treat Rev
Volume : 40(9)
Pages : 1089-95

First international consensus guidelines for breast cancer in young women (BCY1).

Authors : Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meirow D, Peccatori F, Kaufmann B, Cardoso F
Year : 2014
Journal : Breast
Volume : 23(3)
Pages : 209-20

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX st

Authors : Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA, + collaborators (among others :, Deleporte A
Year : 2014
Journal : BMC Cancer
Volume : 14
Pages : 897

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case.

Authors : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart-Gebhart M
Year : 2014
Journal : Eur. J. Cancer
Volume : 50(18)
Pages : 3089-97

Huisartsen staan machteloos tegenover kanker, Artsenkran

Authors : Awada A
Year : 2014
Journal : Artsenkrant
Volume : 2350
Pages : 90c

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Authors : Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(29)
Pages : 3212-20